Advertisement
The projections are based on Young's analysis of adult and human embryonicstem cell products currently sold or in development for the orthopedics,cardiovascular, anti-inflammatory, diabetes, nerve repair and dental markets.
Advertisement
"In recent months we've seen the largest stem cell product purchases inthis fast-growing industry," Young said. "Physicians have already treatedseveral thousands of patients in the United States with stem cell products.Moreover, the results of the clinical trials involving these types of productshave been very impressive. This is a transformational year with the first-everhuman embryonic stem cell products expected to enter the clinic."
Young will provide additional market data at the 3rd Annual Stem CellSummit, which will take place Feb. 26 in New York City. The meeting is slatedto be the largest gathering of stem cell company executives, scientists,investors and physicians. Attendees will learn about the investmentopportunities in the stem cell marketplace, the groundbreaking stem cellproducts physicians are using today, and the growing market potential in termsof revenues. More information, including attendee registration details, isavailable at www.stemcellsummit.com.
Young has more than 25 years of experience as an analyst. He is thepresident of RRY Publications and the organizer of the Stem Cell Summit.Contacts: Wendy Lau Russo Partners, LLC 212-845-4272 [email protected]
SOURCE RRY Publications
